I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The virtual conference is scheduled for February 11-12, 2025.

The company's management team will deliver a presentation on Tuesday, February 11, 2025, from 4:00 to 4:30 PM ET. The presentation will be accessible via webcast, and the company will also participate in one-on-one meetings during the conference.

News Market Reaction – IMAB

+0.94%

+0.94% Session move

In the trading session that priced this news, IMAB gained 0.94%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35^th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.

Details are as follows:

Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Conference Date:		February 11-12, 2025
Format:		Company Presentation and one-on-one meetings
Presentation Time:		Tuesday, February 11, 2025, 4:00 to 4:30 PM ET
Webcast Link:		https://wsw.com/webcast/oppenheimer39/imab/2739496

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.

Investor & Media Contacts

PJ Kelleher
LifeSci Advisors
+1 617-430-7579
pkelleher@lifesciadvisors.com

IR@imabbio.com

FAQ

When is I-Mab (IMAB) presenting at the Oppenheimer Healthcare Conference 2025?

I-Mab is scheduled to present on Tuesday, February 11, 2025, from 4:00 to 4:30 PM ET.

How can investors watch I-Mab's presentation at the Oppenheimer Conference?

Investors can watch I-Mab's presentation through the webcast link: https://wsw.com/webcast/oppenheimer39/imab/2739496

What type of meetings will I-Mab participate in at the Oppenheimer Conference 2025?

I-Mab will participate in a company presentation and one-on-one meetings during the conference.

Is the Oppenheimer Healthcare Conference 2025 virtual or in-person?

The Oppenheimer's 35th Annual Healthcare Life Sciences Conference is being held virtually.

What is I-Mab's primary business focus according to the conference announcement?

I-Mab is focused on the development of precision immuno-oncology agents for the treatment of cancer.